I wore Meta's $499 prescription Ray-Bans for 6 weeks: They're stylish but not for me

This looks more like a channel-expansion SKU than a true product inflection. The prescription angle broadens the addressable audience, but the combination of premium pricing and fit friction suggests early demand will be concentrated among existing optical buyers rather than driving a new consumer wave. That is structurally better for ESLOY than for META: the optical platform, fitting process, and downstream lens economics are where the recurring value sits, while the hardware OEM still bears the burden of educating a skeptical market.

Second-order, the economics likely shift value away from the device itself and toward the prescription workflow. If these glasses gain any traction, the winner is the company that controls lens fulfillment, retail distribution, and repeat visits; the loser is the pure hardware narrative that needs scale to matter. For GOOGL, this is not a near-term competitive threat to core advertising, but it does keep Meta in the race for the next user interface and marginally raises the strategic value of wearables over the next 6-18 months.

The market should be careful not to extrapolate a reviewable consumer product into a profit pool. Over the next 1-3 months, the key catalyst is not the review sentiment itself but actual sell-through, return rates, and whether prescription users adopt this as an everyday device rather than a novelty. The bearish thesis on META is falsified if Meta starts showing meaningful attach rates, repeat usage, or retail expansion; absent that, this remains an optionality story with limited near-term P&L impact.